Completed PHASE3 INTERVENTIONAL 2-arm NCT01257386

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

Sponsor: Tillotts Pharma AG

Updated 5 times since 2017 Last updated: Apr 3, 2013 Started: Nov 30, 2010 Primary completion: Aug 31, 2012 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01257386, this PHASE3 trial focuses on Active Ulcerative Colitis and remains completed. Sponsored by Tillotts Pharma AG, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tillotts Pharma AG
Zeria Pharmaceutical

Data source: Tillotts Pharma AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China